Companies Take Aim at MRSA Infections.

Companies Take Aim at MRSA Infections. P T. 2016 Feb;41(2):126-8 Authors: Fellner C Abstract Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most widespread and virulent nosocomial pathogens. The late-stage clinical pipeline includes an array of proposed new treatments aimed at MRSA-related skin infections and pneumonia. PMID: 26909004 [PubMed]
Source: P and T - Category: Drugs & Pharmacology Tags: P T Source Type: research

Related Links:

ón R Abstract Ceftobiprole, a novel last generation parenteral cephalosporin, has an extended spectrum of activity, notably against methicillin-resistant Staphylococcus aureus (MRSA), ampicillin-susceptible enterococci, penicillin-resistant pneumococci, Enterobacterales and susceptible Pseudomonas aeruginosa. It exerts an inhibitory action on essential peptidoglycan transpeptidases, interfering with cell wall synthesis. The inhibitory action of ceftobiprole through binding to abnormal PBPs like PBP2a in methicillin-resistant staphylococci and PBP2b and PBP2x in the case of β-lactam-resistant pneumococc...
Source: Revista Espanola de Quimioterapia - Category: Drugs & Pharmacology Authors: Tags: Rev Esp Quimioter Source Type: research
Since the introduction of the concept of healthcare-associated pneumonia (HCAP) in the 2005 update on the treatment of nosocomial pneumonias by the American Thoracic Society and the Infectious Diseases Society of America [1], there has been considerable controversy over whether this new category has been helpful or harmful. The core of the problem is the tension between clinicians perceiving that missing a methicillin-resistant Staphylococcus aureus (MRSA) or Pseudomonas aeruginosa may have dire consequences for their patient and the goals of antibiotic stewardship in reducing the use of too broad spectrum antibiotics driv...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Editorials Source Type: research
In conclusion, contrary to the situation in vitro, AZM was effective against MRSA growth in vivo in our pneumonia model, substantially improving survival. The suppressive effect on MRSA growth at the initial stage of pneumonia could underlie the potential mechanism of AZM action against MRSA pneumonia. PMID: 31235625 [PubMed - as supplied by publisher]
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research
CONCLUSIONS: DM patients with poor glucose control are more susceptible to MRSA infection. They suffer from higher antimicrobial resistance, a higher co-infection rate, and much severer pneumonia than non-DM. MRSA itself is an independent risk factor for mortality in all patients. PMID: 31205100 [PubMed - in process]
Source: Chinese Medical Journal - Category: General Medicine Authors: Tags: Chin Med J (Engl) Source Type: research
In this study, we investigated the effects of short-chain fatty acids, metabolites produced by commensal bacteria, on the growth of S. aureus both in vitro and in vivo. Sodium propionate (NaP) most potently inhibited the growth of MRSA and multidrug-resistant clinical isolates. Of note, only NaP, but not NaA or NaB, ameliorated MRSA skin infection, significantly lowering bacterial load, excessive cytokine production, and the size and weight of abscesses approximately by two-fold. In addition, interestingly, S. aureus deficient of lipoteichoic acids (LTA) or wall teichoic acids (WTA), which are important in bacterial physio...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
CONCLUSIONS: There are limited data to support use of TMP-SMX, clindamycin, doxycycline, or minocycline in MRSA pneumonia treatment. Randomized controlled trials are required to determine the effectiveness of these antibiotics. Clinicians should base their decision to use these agents on a case-by-case basis depending on clinical status and susceptibility results. PMID: 31177803 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Tags: Ann Pharmacother Source Type: research
Abstract The use of a drug administration plan and therapeutic drug monitoring (TDM) based on pharmacokinetic-pharmacodynamic (PK-PD) analysis is important for the effective use of antimicrobial agents to treat infections. We focused on the use of beta-lactam agents, anti-methicillin-resistant Staphylococcus aureus (MRSA) agents, and an antifungal agent as antimicrobial agents and examined their efficacy in patients under special clinical conditions from the viewpoint of safety and TDM. Our PK-PD analysis of the use of an administration plan to set an optimum serum level for beta-lactam agents or anti-MRSA drugs f...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - Category: Drugs & Pharmacology Authors: Tags: Yakugaku Zasshi Source Type: research
Lemierre ’s syndrome is classically precipitated by oropharyngeal infections that progress to suppurative internal jugular vein thrombophlebitis via direct extension. Metastatic pneumonia from septic emboli is nearly universal and bacterial seeding frequently results in disseminated septic foci. Fusobacter ium necrophorum is the most commonly reported etiologic agent, though methicillin-resistant Staphylococcus aureus (MRSA) is an emerging pathogen and a myriad of oropharyngeal flora must be covered until blood cultures return.
Source: The Journal of Emergency Medicine - Category: Emergency Medicine Authors: Tags: Clinical Communications: Adults Source Type: research
Conclusion: PVL expression is high among clinical S. aureus strains among Gambian patients. Reporting of PVL-SA clinical infections is necessary to enable the monitoring of the clinical impact of these strains in the population and guide prevention of the spread of virulent PVL-positive CA-MRSA strains.
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
Ticagrelor is a reversible platelet adenosine diphosphate P2Y12 receptor (P2Y12) inhibitor and is quite effective as an antiplatelet agent. New research suggests an antibiotic effect for ticagrelor and the researchers suggest that further research may lead to development of a new class of antibiotics [1]. In fact there is a global need for new antibiotics, which are conspicuous by their absence in the current scenario of multidrug resistant organisms. The study published as a Research Letter in JAMA Cardiology reports on the ‘Antibacterial Activity of Ticagrelor in Conventional Antiplatelet Dosages Agains...
Source: Cardiophile MD - Category: Cardiology Authors: Tags: Cardiology Source Type: blogs
More News: Drugs & Pharmacology | Infectious Diseases | MRSA | Pneumonia | Skin | Staphylococcus Aureus | Superbugs